13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001778253
Total reported value
$928.2M
$928.2M
141 檔
44.4%
During the Q1 2025 filing period, Ikarian Capital, LLC (CIK: 0001778253) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $928.2M across 141 reported positions.
In Q1 2025, Ikarian Capital, LLC adopted a defensive or profit-taking posture, trimming 10 positions and completely liquidating 112 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 23.78% | — | — | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 15.27% | -0.49% | EXIT | |
| 3 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 5.46% | — | — | |
| 4 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.18% | -0.86% | -18.51% | |
| 5 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 3.07% | +0.03% | -20.19% | |
| 6 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.02% | -0.94% | EXIT | |
| 7 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.16% | — | +1.36% | |
| 8 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.92% | -0.22% | +140.29% | |
| 9 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.36% | — | -25.06% | |
| 10 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.33% | — | +46.92% | |
| 11 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.24% | — | -32.75% | |
| 12 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.22% | — | +23.12% | |
| 13 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.19% | — | +185.71% | |
| 14 | TRUP | Trupanion Inc | Stock-Other | 1.10% | — | — | |
| 15 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.09% | — | -40.00% | |
| 16 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.05% | — | — | |
| 17 | BHVN | Biohaven Ltd. | Stock-Other | 1.03% | +0.92% | — | |
| 18 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 1.02% | — | -27.87% | |
| 19 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.02% | — | +62.50% | |
| 20 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.93% | +0.28% | — | |
| 21 | PCVX | Vaxcyte Inc | Stock-Other | 0.93% | +0.41% | — | |
| 22 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.91% | — | — | |
| 23 | ACLXGBX | Arcellx Inc | Stock-Other | 0.90% | — | — | |
| 24 | VIR | Vir Biotechnology Inc | Stock-Other | 0.85% | -0.21% | EXIT | |
| 25 | IMVT | Immunovant Inc | Stock-Other | 0.84% | — | +33.07% | |
| 26 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.82% | +0.84% | NEW | |
| 27 | INSM | Insmed Inc | Stock-Healthcare | 0.80% | -0.06% | EXIT | |
| 28 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.76% | — | +139900.00% | |
| 29 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 0.75% | — | -28.60% | |
| 30 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.74% | -6.65% | EXIT | |
| 31 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.70% | — | +94.39% | |
| 32 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.70% | +0.42% | -26.61% | |
| 33 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.68% | +1.51% | — | |
| 34 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.66% | — | +361.51% | |
| 35 | ACOG | Alpha Cognition Inc | Stock-Other | 0.63% | +0.18% | +28.05% | |
| 36 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.60% | +0.01% | — | |
| 37 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.59% | +0.36% | +89.06% | |
| 38 | FBRX | Forte Biosciences Inc | Stock-Other | 0.58% | -0.20% | — | |
| 39 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.56% | — | -7.04% | |
| 40 | ✓ | Stock-Other | 0.50% | — | — | ||
| 41 | STIM | Neuronetics Inc | Stock-Other | 0.50% | +0.02% | — | |
| 42 | CAPR | Capricor Therapeutics Inc | Stock-Other | 0.47% | +0.31% | -39.49% | |
| 43 | INCY | Incyte CORP | Stock-Healthcare | 0.45% | — | — | |
| 44 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.45% | — | +76.92% | |
| 45 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.44% | +0.27% | — | |
| 46 | JANX | Janux Therapeutics Inc | Stock-Other | 0.43% | — | +73.64% | |
| 47 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.43% | — | -9.00% | |
| 48 | ARCT | Arcturus Therapeutics Holdin | Stock-Other | 0.42% | — | +62.50% | |
| 49 | QURE | uniQure N.V. | Stock-Other | 0.39% | -0.12% | EXIT | |
| 50 | CPIX | Cumberland Pharmaceuticals | Stock-Other | 0.39% | +0.20% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | +15.2% | — | Add |
| 2 | SRPT | Sarepta Therapeutics Inc | +1% | +46.92% | Add |
| 3 | TGTX | Tg Therapeutics Inc | +0.7% | -27.87% | Add |
| 4 | CYTK | Cytokinetics Inc | +0.6% | — | Add |
| 5 | VKTX | Viking Therapeutics Inc | +0.4% | — | Trim |
| 6 | PCVX | Vaxcyte Inc | +0.1% | — | Trim |
| 7 | FULC | Fulcrum Therapeutics Inc | -0.1% | — | Add |
| 8 | ACRS | Aclaris Therapeutics Inc | -0.1% | -56.89% | Add |
| 9 | KOD | Kodiak Sciences Inc | -0.3% | +12.73% | Add |
| 10 | RCUS | Arcus Biosciences Inc | -0.4% | -68.55% | Trim |
| 11 | LYRAGBP | Lyra Therapeutics Inc | -0.4% | — | Add |
| 12 | ✓ | -0.4% | — | Trim | |
| 13 | ALLKGUSD | Allakos Inc | -1% | +20.58% | Add |
| 14 | ALEC | Alector Inc | -1.1% | — | Add |
| 15 | INCY | Incyte CORP | -1.2% | — | Trim |
| 16 | RLMD | Relmada Therapeutics Inc | -1.3% | — | Trim |
| 17 | MGNX | Macrogenics Inc | -1.6% | — | Trim |
| 18 | CLDX | Celldex Therapeutics Inc | -2.6% | -82.68% | Trim |
| 19 | APLSUSD | Apellis Pharmaceuticals Inc | -2.9% | +1986.81% | Trim |
| 20 | ALNY | Alnylam Pharmaceuticals Inc | -5.7% | — | Trim |
| 21 | SPY | Ss Spdr S&p 500 ETF Trust-us | — | NEW | New buy |
| 22 | BIIB | Biogen Inc | — | EXIT | Sold out |
| 23 | CRSP | CRISPR Therapeutics AG | — | EXIT | Sold out |
| 24 | NTLA | Intellia Therapeutics Inc | — | EXIT | Sold out |
| 25 | CORT | Corcept Therapeutics Inc | — | NEW | New buy |
| 26 | FLNA | Filana Therapeutics Inc | — | EXIT | Sold out |
| 27 | SG7 | Sage Therapeutics Inc | — | EXIT | Sold out |
| 28 | ✓ | Horizon Therapeutics PLC | — | EXIT | Sold out |
| 29 | BBIO | Bridgebio Pharma Inc | — | NEW | New buy |
| 30 | TARS | Tarsus Pharmaceuticals Inc | — | NEW | New buy |
| 31 | RETAEUR | Reata Pharmaceuticals Inc-a | — | EXIT | Sold out |
| 32 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 33 | BHC | Bausch Health Cos Inc | — | EXIT | Sold out |
| 34 | CCXIEUR | Chemocentryx Inc | — | EXIT | Sold out |
| 35 | LKFT | Lakefront Biotherapeutic-adr | — | EXIT | Sold out |
| 36 | ITCIEUR | Intra-cellular Therapies Inc | — | EXIT | Sold out |
| 37 | ASNSUSD | X4 Pharmaceuticals Inc | — | EXIT | Sold out |
| 38 | ✓ | — | EXIT | Sold out | |
| 39 | CRNX | Crinetics Pharmaceuticals In | — | NEW | New buy |
| 40 | ZGNXEUR | Zogenix Inc | — | EXIT | Sold out |
| 41 | OCUL | Ocular Therapeutix Inc | — | EXIT | Sold out |
| 42 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 43 | XENE | Xenon Pharmaceuticals Inc | — | EXIT | Sold out |
| 44 | ARKG | Ark Genomic Revolution ETF | — | EXIT | Sold out |
| 45 | CMRXEUR | Chimerix Inc | — | EXIT | Sold out |
| 46 | MCRB1EUR | Seres Therapeutics Inc | — | EXIT | Sold out |
| 47 | FGENEUR | Fibrogen Inc | — | EXIT | Sold out |
| 48 | ✓ | Rapt Therapeutics Inc | — | EXIT | Sold out |
| 49 | SRRK | Scholar Rock Holding CORP | — | NEW | New buy |
| 50 | MIST | Milestone Pharmaceuticals In | — | EXIT | Sold out |
According to official SEC Form 13F filings, Ikarian Capital, LLC reported a total U.S. public equity portfolio value of $928.2M across 141 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPY, LLY, CORT) accounted for 44.4% of total reported equity market value during Q1 2025.
Top New Position Initiated
SPY
市值: $193.0M
Top Position Liquidated / Trimmed
BIIB
前期市值: $137.1M
During Q1 2025, Ikarian Capital, LLC's top holdings by market value included SPY (23.8%)、LLY (15.3%)、CORT (5.5%). The largest single position, SPY, represented 23.8% of total portfolio value.
In Q1 2025, Ikarian Capital, LLC made 200 total portfolio adjustments, initiating 68 new buys, adding to 10 positions, trimming 10 holdings, and fully liquidating 112 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.